Midiana (Drospirenone, Ethinylestradiol)

Drospirenone acts as a progestogen, while ethinylestradiol is an estrogen. Together they suppress the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation. The progestogen also thickens cervical mucus and the estrogen stabilises the endometrium, reducing the chance of fertilisation and implantation.

The dosing regimen for Midiana is determined by the prescribing clinician. Typically, it is taken as a daily tablet according to a specific cycle, but the exact strength, number of tablets per pack, and duration are set by the healthcare provider based on individual needs.

Midiana is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued. Limited data are available for breastfeeding; clinicians usually advise against use while nursing unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the Midiana product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Midiana contains drospirenone, a progestogen with anti‑androgenic and mild diuretic properties, which may offer advantages such as reduced water retention compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ slightly.

Midiana tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Midiana is taken orally, usually once daily at the same time each day. The tablets are swallowed whole with water and are not to be split, crushed, or chewed. Patients should follow the specific cycle schedule provided by their prescriber.

The most serious risks include venous thromboembolism (deep vein thrombosis, pulmonary embolism), arterial events such as stroke or myocardial infarction, and severe allergic reactions. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid use.

Midiana is contraindicated in women who are pregnant, have known thrombophilia, a history of estrogen‑dependent tumors, uncontrolled hypertension, active liver disease, or who are smokers over the age of 35. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.